Business
Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update
2025 total revenue of $673 million,Crysvita® revenue of $481 million and Dojolvi® revenue of $96 million 2026 total revenue from current products expected to be between $730 million to $760 million Initiated a strategic restructuring plan to significantly reduce and focus expenses and headcount, reiterate path to profitability in 2027 2026 catalysts include two potential approvals and expected pivotal Phase 3 data from the GTX-102 Phase 3 Aspire study for Angelman syndrome NOVATO, Calif., Feb. 1
About this update from Ultragenyx Pharmaceutical Inc.
[{"type":"image","alt":"Ultragenyx Pharmaceutical Inc.","displaySize":"","headline":null,"caption":"Ultragenyx Pharmaceutical Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":113,"url":"https://media.zenfs.com/en/globenewswire.com/98c2a760a19e68caceb0f8447079e784"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/WFxQplTkxt9FOMPM4ARqBw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/98c2a760a19e68caceb0f8447079e784","width":300,"height":113}},"lazy":false},{"type":"text","content":"","length":0,"tagName":"p"},{"type":"text","content":"2025 total revenue of $673 million,Crysvita® revenue of $481 million and Dojolvi® revenue of $96 million","length":105,"tagName":"p"},{"type":"text","content":"2026 total revenue from current products expected to be between $730 million to $760 million","length":92,"tagName":"p"},{"type":"text","content":"Initiated a strategic restructuring plan to significantly reduce and focus expenses and headcount, reiterate path to profitability in 2027 ","length":138,"tagName":"p"},{"type":"text","content":"2026 catalysts include two potential approvals and expected pivotal Phase 3 data from the GTX-102 Phase 3 Aspire study for Angelman syndrome","length":140,"tagName":"p"},{"type":"text","content":"NOVATO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today reported its financial results for the quarter and year ended December 31, 2025.","length":329,"tagName":"p"},{"type":"text","content":"“The year ahead marks an important turning point for the company, as we approach two potential product launches and a pivotal data readout that, together, could significantly accelerate our commercial revenue trajectory,” said Emil D. Kakkis, M.D., Ph.D., chief executive officer and president of Ultragenyx. “We are implementing a strategic restructuring plan to reduce our operating expenses and ensure our resources are squarely aligned with our highest-impact opportunities, while leading the future of rare disease with multiple first ever treatments.”","length":557,"tagName":"p"},{"type":"text","content":"Fourth Quarter 2025 Selected Financial Data Tables and Financial Res...